PHP
RCUS icon

Parkman Healthcare Partners’s Arcus Biosciences RCUS Stock Holding History

Parkman Healthcare Partners’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$26.1M Buy
1,207,274
+238,672
+25% +$5.15M 2.69% 10
2025
Q4 		$23.1M Buy
968,602
+315,922
+48% +$6.45M 2.2% 14
2025
Q3 		$8.88M Buy
652,680
+53,070
+9% +$552K 0.93% 40
2025
Q2 		$4.88M Sell
599,610
-616,019
-51% -$5.26M 0.56% 62
2025
Q1 		$9.54M Sell
1,215,629
-58,160
-5% -$674K 1.13% 32
2024
Q4 		$19M Buy
1,273,789
+248,035
+24% +$4.05M 2.53% 13
2024
Q3 		$15.7M Buy
1,025,754
+610,219
+147% +$9.62M 2% 14
2024
Q2 		$6.33M Buy
415,535
+155,615
+60% +$2.51M 0.85% 42
2024
Q1 		$4.91M Buy
259,920
+12,256
+5% +$212K 0.6% 53
2023
Q4 		$4.73M Buy
247,664
+42,555
+21% +$680K 0.67% 48
2023
Q3 		$3.68M Buy
205,109
+85,060
+71% +$1.71M 0.67% 43
2023
Q2 		$2.44M Buy
120,049
+17,062
+17% +$325K 0.42% 67
2023
Q1 		$1.88M Buy
102,987
+15,527
+18% +$297K 0.41% 59
2022
Q4 		$1.81M Sell
87,460
-50,434
-37% -$1.39M 0.48% 59
2022
Q3 		$3.61M Sell
137,894
-33,320
-19% -$881K 1.03% 36
2022
Q2 		$4.34M Buy
171,214
+3,893
+2% +$95.3K 1.6% 22
2022
Q1 		$5.28M Buy
167,321
+50,222
+43% +$1.68M 1.55% 24
2021
Q4 		$4.74M Sell
117,099
-119,538
-51% -$4.64M 1.05% 30
2021
Q3 		$8.25M Sell
236,637
-10,000
-4% -$311K 2.09% 17
2021
Q2 		$6.77M Sell
246,637
-69,245
-22% -$1.98M 1.48% 23
2021
Q1 		$8.87M Buy
315,882
+84,124
+36% +$2.93M 2.06% 14
2020
Q4 		$6.02M Sell
231,758
-3,280
-1% -$79.4K 1.54% 25
2020
Q3 		$4.03M Buy
235,038
+75,038
+47% +$1.68M 1.07% 39
2020
Q2 		$3.96M Buy
+160,000
New +$4.32M 1.12% 34

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Parkman Healthcare Partners's RCUS Position: Q1 2026 in Review

Parkman Healthcare Partners increased its Arcus Biosciences (RCUS) stake by 25% in Q1 2026, buying an estimated $5.15M and bringing the position to 1,207,274 shares worth $26.1M. The position accounts for 2.69% of the portfolio, ranked #10.

Parkman Healthcare Partners first reported a position in RCUS in Q2 2020 and has held it in 24 quarters since. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.

  • Parkman Healthcare Partners held 1,207,274 shares of Arcus Biosciences worth $26.1M as of Q1 2026.
  • Parkman Healthcare Partners bought 238,672 Arcus Biosciences shares in Q1 2026, an estimated $5.15M.
  • Arcus Biosciences made up 2.69% of Parkman Healthcare Partners's portfolio in Q1 2026, its #10 holding.
  • Parkman Healthcare Partners first reported a position in Arcus Biosciences in Q2 2020 and has held it in 24 quarters since.
  • 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.

Based on Parkman Healthcare Partners's 13F filing for Q1 2026, filed 15 May 2026.